Programme

Welcome Reception
The Queen Elizabeth II Conference Centre

Please click here to download the final announcement 

THURSDAY 1 DECEMBER 2011

07:30 Registration opens
08:30 Welcome and introduction
C Griffiths (Manchester, UK)
J Barker (London, UK)

GENETICS
08:45 - 09:30 Keynote lecture
Completing the genetic map of psoriasis and its future implications
J T Elder (Michigan, USA)
09:30 - 09:45 FC01: Detection of copy number variants at new psoriasis loci identified by genome-wide association studies
M Apel (Nuremberg Germany)
09:45 - 10:00 FC02: Replication of eighteen psoriasis genetic associations in Caucasians
R P Nair (Michigan USA)
10:00 - 10:15 FC03: A homozygous mutation of IL36RN gene leads to Interleukin-36 receptor antagonist deficiency and causes generalised pustular psoriasis
A Smahi (Paris, France)
10.15 - 10.45 Coffee break
10:45 - 11:15 Invited speaker
Common pathways of autoimmune disease identified by GWAS
M A Brown (Brisbane, Australia)
11:15 - 11:30 FC04: Genetic support for a role for the inflammasome in psoriasis
A-K Ekman (Linköping, Sweden)
11:30 - 11:45 FC05: Genetic and functional
characterization of the RNF114 psoriasis susceptibility gene suggests a pathogenic role for the dysregulation of innate antiviral immunity
F Capon (London UK)
11:45 - 12:00 FC06: Expression of Late Cornified Envelope (LCE) genes indicates a role for insufficient skin barrier repair in pathogenesis of psoriasis.
J Bergboer (Nijmegen, The Netherlands)
12:00 - 12:15 FC07: Functional investigation of the psoriasis protective IL23R R381Q gene variant reveals impaired IL-23-induced Th17 response.
P Di Meglio (London, UK)
12:15 - 12:45 Invited speaker
Bio-informatic approaches to the study of complex diseases
A Butte (Stanford, USA)
12.45 - 13.45 Lunch and poster viewing

CO-MORBIDITIES AND OUTCOME
MEASURES

13.45 - 14.15 Invited speaker
Using biobanks to understand disease risk
Sir R Collins (Oxford, UK)
14.15 - 14:30 FC08: HLA- B*27 and HLA-C*0602 are risk alleles for psoriatic arthritis among psoriasis patients.
D Gladman (Toronto Canada)
14:30 - 14:45 FC09: Psoriasis patients with nail disease have a greater magnitude of underlying systemic subclinical enthesopathy than psoriasis cases with normal nails - a novel explanation for why nail disease predicts arthropathy
Zoe Ash ( Leeds, UK)
14:45 - 15:00 FC10: Human epidermal Langerhans cells replenish skin xenografts and are depleted by allo-reactive T cells in vivo: a model to study psoriasis
R E Schopf, (Mainz, Germany)
15:00 - 15:15 FC11: Systematic review of the incidence and prevalence of psoriasis
D Ashcroft (Manchester, UK)
15.15 - 15.45 Invited speaker
Health outcomes of psoriasis J Gelfand (Pennsylvania, USA)
15:45 - 16:15 Tea
16.15 - 17.15 Celgene Corporation sponsored symposium
17.30 - 18.30 Pfizer sponsored symposium
18.30 Close of Congress sessions
18.30 - 19.30 Welcome Reception
Queen Elizabeth II Conference Centre

FRIDAY 2 DECEMBER 2011
IMMUNOLOGY AND IMMUNITY

08.15 - 09:15 MSD sponsored symposium
09:30 - 10:00 Invited speaker
Linking innate and adaptive immunity in psoriasis
E Prens (Rotterdam, The Netherlands)
10:00 - 10:30 Coffee break
10:30 - 10:45 FC12: Reconstructed human skin populated with activated T cells: A new in vitro model for psoriasis
Ellen van den Bogaard (Nijmegen, The Netherlands)
10:45 - 11:00 FC13: IL-17A is an essential cytokine to sustain pathogenic cell activation and inflammatory gene circuits in psoriasis vulgaris.
James Krueger (Indianapolis USA)
11:00 - 11:30 Invited speaker
Human memory T-cell heterogeneity in health and disease F Sallusto (Bellinzona, Switzerland)
11:30 - 11:45 FC14: Streptococcus induces simultaneous Th1, Th17, Th22 responses, and epidermal cell activation/hyperplasia in vivo, through the interaction of circulating CLA+ T cells and autologous epidermal cells in psoriasis
L Santamaria-Babí (Barcelona, Spain)
11:45 - 12:00 FC15: Single cell analysis confirms antigen-specific clonal T cell expansions within psoriatic skin lesions
Joerg Prinz (Munich, Germany)
12:00 - 13:25 Lunch and poster viewing
13.25 - 14.10 Keynote lecture
The discovery-care continuum for psoriasis
C Griffiths (Manchester, UK)
14.10 - 14.25 FC16: Regulation and functional impact of novel IL-1 family members in psoriatic inflammation.
Miriam Wittmann (Leeds, UK)
14:25 - 14:40 FC17: Interleukin(IL)-19 is a novel component of the immunological cascades in psoriasis
Ellen Witte (Berlin, Germany)
14.45 - 15.45 Janssen Sponsor Symposium
15.45 - 16.15 Tea
16:15 - 17:15 Abbott Sponsor Symposium
17:15 Close of Congress sessions
19.30 Congress Banquet
Royal Automobile Club

SATURDAY 3 DECEMBER 2011
TARGETED THERAPEUTICS

09.00 - 09.15 FC18: Jak/STAT expression and activation in psoriasis R M Andrés Ejarque (Aarhus, Denmark)
09:15 - 09:30 FC19: CT327: a novel breakthrough therapy targeting the NGF/TrkA kinase pathway in psoriasis
S Traversa (Colleretto Giacosa (TO), Italy)
09:30 - 09:45 FC20: TNFAIP3 Polymorphisms and Age at Onset Are Associated with Response to TNF Blockade in Psoriasis
T Tejasvi (Michigan, USA)
09:45 - 10:00 FC21: Results of a Single Ascending Dose Study to Assess the Safety and Tolerability of CNTO 1959 Following IV or SC Administration in Healthy Subjects and in Subjects with Moderate to Severe Psoriasis
J Krueger (New York, USA)
10.00 - 10:30 Invited speaker
Early intervention with biologics for psoriasis: lessons from rheumatoid arthritis
P Emery (Leeds, UK)
10:30 - 11:00 Coffee Break
11:00 - 11:30 Invited speaker
Optimising the drug discovery pipeline
T Jung (Basel, Switzerland)
11:30 - 11:45 FC22: Early Tissue responses in psoriasis to the anti-TNF-α biologic etanercept suggest reduced IL-17R expression and signaling
A Johnston (Michigan, USA)
11:45 - 12:00 FC23: Presence of HLA-Cw6 but not LCE3C_LCE3B deletion influences clinical response to ustekinumab in psoriasis patients
A Costanzo (Rome, Italy)
12:00 - 12:45 Keynote lecture
The changing landscape of psoriasis therapy P van de Kerkhof
(Nijmegen, The Netherlands)
12.45 Presentation of poster prizes and close of Congress
J Barker (London, UK)
C Griffiths (Manchester, UK)